Review

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia

Constantine E. Kosmas 1,*, Alba Muñoz Estrella 2, Andreas Sourlas 3, Delia Silverio 4, Elizabeth Hilario 4, Peter D. Montan 4 and Eliscer Guzman 5

1 Department of Medicine, Division of Cardiology, Mount Sinai Hospital, New York, NY 11357, USA
2 Department of Medicine, Mount Sinai St. Luke’s-West Hospital, New York, NY 10025, USA; alba.munoz.estrella@gmail.com
3 School of Medicine, University of Crete, 71003 Heraklion, Greece; med3553@edu.med.uoc.gr
4 Cardiology Clinic, Cardiology Unlimited, PC, New York, NY 10033, USA; deliasg10@gmail.com (D.S.); bethhilario@hotmail.com (E.H.); drpetermontan@gmail.com (P.D.M.)
5 Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY 10467, USA; eliscer@hotmail.com
* Correspondence: cekosmas1@gmail.com; Tel.: +1-646-734-7969

Academic Editor: Ahmed Bakillah

Received: 29 June 2018; Accepted: 11 July 2018; Published: 13 July 2018

Abstract: The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal degradation, offered an additional route through which plasma LDL-cholesterol (LDL-C) levels can be controlled. Initially, the therapeutic approaches to reduce circulating levels of PCSK9 were focused on the use of monoclonal antibodies. To that effect, evolocumab and alirocumab, two human monoclonal antibodies directed against PCSK9, given on a background of statin therapy, have been shown to markedly decrease LDL-C levels and significantly reduce cardiovascular risk. The small interfering RNA (siRNA) molecules have been used recently to target the hepatic production of PCSK9, siRNA interferes with the expression of specific genes with complementary nucleotide sequences by affecting the degradation of mRNA post-transcription, thus preventing translation. Inclisiran is a long-acting, synthetic siRNA directed against PCSK9 and it has been shown to significantly decrease hepatic production of PCSK9 and cause a marked reduction in LDL-C levels. This review aims to present and discuss the current clinical and scientific evidence pertaining to inclisiran, which is a new promising agent in the management of hypercholesterolemia.

Keywords: proprotein convertase subtilisin-kexin type 9 (PCSK9); small interfering RNA (siRNA); inclisiran; low-density lipoprotein-cholesterol (LDL-C); cardiovascular disease (CVD); cardiovascular risk

1. Introduction

Cardiovascular disease (CVD) is the number one cause of death worldwide. An estimated 17.7 million people died from CVD in 2015, representing 31% of all global deaths [1]. Hypercholesterolemia is a major known risk factor for cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) lowering has been unequivocally shown to cause a significant reduction in cardiovascular risk in both primary and secondary prevention [2,3]. Statins are the standard of care and have a proven efficacy in LDL-C lowering and in the reduction of CVD risk [4,5]. However, there is considerable variability in individual responses to statins [6] and many individuals at risk for CVD fail to achieve LDL-C goals [7,8]. Furthermore, several patients demonstrate intolerance to statins, mostly due to myalgias and weakness [9]. These factors necessitate research for the development of
new additional therapies with a favorable side effect profile that would improve our ability to achieve LDL-C goals and decrease CVD risk [10].

The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9) in 2003 [11], a serine protease which binds to the LDL receptors and targets the receptors for lysosomal degradation, thereby reducing their recycling and decreasing the removal rate of circulating LDL-C [12], offered an additional route through which plasma LDL-C levels can be controlled [13]. Initially, the therapeutic approaches to reduce circulating levels of PCSK9 were focused on the use of monoclonal antibodies. To that effect, evolocumab and alirocumab, two human monoclonal antibodies directed against PCSK9, given on a background of statin therapy, have been shown to markedly decrease LDL-C levels and significantly reduce cardiovascular risk [14,15]. Circulating PCSK9 is generated mainly by the liver; hence, therapeutic agents curtailing the hepatic production of PCSK9 may provide an alternative to the use of monoclonal antibodies. Inclisiran is a chemically synthesized small interfering RNA (siRNA) molecule, which targets the hepatic production of PCSK9 and is currently under investigation for its LDL-C lowering effect and potential for cardiovascular risk reduction.

2. siRNAs: Mechanism of Action

siRNAs are ~20–30 nucleotide RNA molecules, which lately have emerged as critical regulators in the expression and function of eukaryotic genomes. These molecules, which may be active in both the somatic and germline lineages of different eukaryotic species, are involved in the regulation of endogenous genes and in the protection of the genome from invasive nucleic acids [16]. In most mammalian cells, long double-stranded RNA induces an interferon response, which contributes to the antiviral defense. This interferon response prompts a generalized shutdown of protein synthesis. As a result, long double-stranded RNA cannot be used for specific gene silencing. On the contrary, siRNAs can evade the radar of the mammalian interferon response and produce strong and specific gene silencing [17]. More specifically, siRNA interferes with the expression of specific genes with complementary nucleotide sequences by affecting the degradation of mRNA post-transcription, thus preventing translation [18].

3. Inclisiran

The siRNA molecule has been used recently to decrease PCSK9 levels. The siRNA molecules follow the natural pathway of RNA interference (RNAi) by binding intracellularly to the RNA-induced silencing complex (RISC), thus enabling it to cleave messenger RNA (mRNA) molecules specifically encoding PCSK9 [19].

Inclisiran is a long-acting, synthetic siRNA directed against PCSK9, which is conjugated to triantennary N-acetylgalactosamine carbohydrates. These carbohydrates bind to abundant liver-expressed asialoglycoprotein receptors, leading to the uptake of inclisiran specifically into the hepatocytes [20,21].

A schematic of the mechanism of action of inclisiran (along with the action of PCSK9, the hepatic production of which is significantly decreased by inclisiran) is shown in Figure 1.
were on treatment with ezetimibe. At day 180, the least-squares mean reductions in LDL-C levels with inclisiran at the dose of 0.400 mg/kg, there was a significant mean reduction in circulating (125 mg weekly for four doses, 250 mg every other week for two doses, and 300 or 500 mg monthly for 2018 Diseases level at 180 days. At enrollment, 73% of the patients were on statin therapy, and 31% of the patients of inclisiran at days 1 and 90. The primary end point was the change in LDL-C level from baseline ≥ single dose of placebo or 200, 300, or 500 mg of inclisiran, or two doses of placebo or 100, 200, or 300 mg LDL-C levels > 70 mg/dL in the presence of a history of atherosclerotic CVD (ASCVD) or > 100 mg/dL trial of inclisiran, administered as a subcutaneous injection, in patients at high risk for CVD with ≥ adult volunteers with serum LDL-C levels ≥ 3.00 mmol/L (116 mg/dL), participants were randomly assigned in a 3:1 ratio to receive one dose of intravenous ALN-PCS (inclisiran), with doses ranging from 0.015 to 0.400 mg/kg, versus placebo. In the group of participants who received treatment with inclisiran at the dose of 0.400 mg/kg, there was a significant mean reduction in circulating PCSK9 and LDL-C levels by 70% and 40%, respectively, as compared with placebo (p < 0.0001 for both comparisons). The proportions of patients affected by treatment-emergent adverse events were similar in the inclisiran and placebo groups (79% vs. 88%, respectively) [22].

In another phase 1 trial, several different doses of inclisiran or placebo were administered subcutaneously to healthy volunteers with an LDL-C level of at least 100 mg/dL. The doses of inclisiran tried were single-dose-injections (25, 100, 300, 500, and 800 mg) or multiple-dose injections (125 mg weekly for four doses, 250 mg every other week for two doses, and 300 or 500 mg monthly for two doses) with or without concurrent statin therapy. Single doses of inclisiran ≥ 300 mg decreased the PCSK9 level by up to a least-squares mean reduction of 74.5% from baseline to day 84, whereas single doses of ≥100 mg lowered LDL cholesterol-C by up to a least-squares mean reduction of 50.6% from baseline. Reductions in the PCSK9 and LDL-C levels were maintained at day 180 for doses of ≥300 mg. All multiple-dose regimens of inclisiran reduced the levels of PCSK9 and LDL-C by up to a least-squares mean reduction of 83.8% and 59.7% from baseline to day 84, respectively. There were no serious adverse events observed with inclisiran and the most common adverse events were cough, musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea [23].

ORION-1 was a phase 2, multicenter, double-blind, placebo-controlled, multiple-ascending-dose trial of inclisiran, administered as a subcutaneous injection, in patients at high risk for CVD with LDL-C levels > 70 mg/dL in the presence of a history of atherosclerotic CVD (ASCVD) or > 100 mg/dL in the absence of a history of ASCVD. A total of 501 patients were randomly assigned to receive a single dose of placebo or 200, 300, or 500 mg of inclisiran, or two doses of placebo or 100, 200, or 300 mg of inclisiran at days 1 and 90. The primary end point was the change in LDL-C level from baseline level at 180 days. At enrollment, 73% of the patients were on statin therapy, and 31% of the patients were on treatment with ezetimibe. At day 180, the least-squares mean reductions in LDL-C levels to 0.015 to 0.400 mg/kg, versus placebo. In the group of participants who received treatment with inclisiran at the dose of 0.400 mg/kg, there was a significant mean reduction in circulating PCSK9 and LDL-C levels by 70% and 40%, respectively, as compared with placebo (p < 0.0001 for both comparisons). The proportions of patients affected by treatment-emergent adverse events were similar in the inclisiran and placebo groups (79% vs. 88%, respectively) [22].

In another phase 1 trial, several different doses of inclisiran or placebo were administered subcutaneously to healthy volunteers with an LDL-C level of at least 100 mg/dL. The doses of inclisiran tried were single-dose-injections (25, 100, 300, 500, and 800 mg) or multiple-dose injections (125 mg weekly for four doses, 250 mg every other week for two doses, and 300 or 500 mg monthly for two doses) with or without concurrent statin therapy. Single doses of inclisiran ≥ 300 mg decreased the PCSK9 level by up to a least-squares mean reduction of 74.5% from baseline to day 84, whereas single doses of ≥100 mg lowered LDL cholesterol-C by up to a least-squares mean reduction of 50.6% from baseline. Reductions in the PCSK9 and LDL-C levels were maintained at day 180 for doses of ≥300 mg. All multiple-dose regimens of inclisiran reduced the levels of PCSK9 and LDL-C by up to a least-squares mean reduction of 83.8% and 59.7% from baseline to day 84, respectively. There were no serious adverse events observed with inclisiran and the most common adverse events were cough, musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea [23].

ORION-1 was a phase 2, multicenter, double-blind, placebo-controlled, multiple-ascending-dose trial of inclisiran, administered as a subcutaneous injection, in patients at high risk for CVD with LDL-C levels > 70 mg/dL in the presence of a history of atherosclerotic CVD (ASCVD) or > 100 mg/dL in the absence of a history of ASCVD. A total of 501 patients were randomly assigned to receive a single dose of placebo or 200, 300, or 500 mg of inclisiran, or two doses of placebo or 100, 200, or 300 mg of inclisiran at days 1 and 90. The primary end point was the change in LDL-C level from baseline level at 180 days. At enrollment, 73% of the patients were on statin therapy, and 31% of the patients were on treatment with ezetimibe. At day 180, the least-squares mean reductions in LDL-C levels

4. Clinical Trials with Inclisiran

In a randomized, single-blind, placebo-controlled, phase 1 dose-escalation study in healthy adult volunteers with serum LDL-C levels ≥ 3.00 mmol/L (116 mg/dL), participants were randomly assigned in a 3:1 ratio to receive one dose of intravenous ALN-PCS (inclisiran), with doses ranging from 0.015 to 0.400 mg/kg, versus placebo. In the group of participants who received treatment with inclisiran at the dose of 0.400 mg/kg, there was a significant mean reduction in circulating PCSK9 and LDL-C levels by 70% and 40%, respectively, as compared with placebo (p < 0.0001 for both comparisons). The proportions of patients affected by treatment-emergent adverse events were similar in the inclisiran and placebo groups (79% vs. 88%, respectively) [22].

In another phase 1 trial, several different doses of inclisiran or placebo were administered subcutaneously to healthy volunteers with an LDL-C level of at least 100 mg/dL. The doses of inclisiran tried were single-dose-injections (25, 100, 300, 500, and 800 mg) or multiple-dose injections (125 mg weekly for four doses, 250 mg every other week for two doses, and 300 or 500 mg monthly for two doses) with or without concurrent statin therapy. Single doses of inclisiran ≥ 300 mg decreased the PCSK9 level by up to a least-squares mean reduction of 74.5% from baseline to day 84, whereas single doses of ≥100 mg lowered LDL cholesterol-C by up to a least-squares mean reduction of 50.6% from baseline. Reductions in the PCSK9 and LDL-C levels were maintained at day 180 for doses of ≥300 mg. All multiple-dose regimens of inclisiran reduced the levels of PCSK9 and LDL-C by up to a least-squares mean reduction of 83.8% and 59.7% from baseline to day 84, respectively. There were no serious adverse events observed with inclisiran and the most common adverse events were cough, musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea [23].

ORION-1 was a phase 2, multicenter, double-blind, placebo-controlled, multiple-ascending-dose trial of inclisiran, administered as a subcutaneous injection, in patients at high risk for CVD with LDL-C levels > 70 mg/dL in the presence of a history of atherosclerotic CVD (ASCVD) or > 100 mg/dL in the absence of a history of ASCVD. A total of 501 patients were randomly assigned to receive a single dose of placebo or 200, 300, or 500 mg of inclisiran, or two doses of placebo or 100, 200, or 300 mg of inclisiran at days 1 and 90. The primary end point was the change in LDL-C level from baseline level at 180 days. At enrollment, 73% of the patients were on statin therapy, and 31% of the patients were on treatment with ezetimibe. At day 180, the least-squares mean reductions in LDL-C levels...
were 27.9 to 41.9% in the patients who received a single dose of inclisiran and 35.5% to 52.6% in the
patients who received two doses (p < 0.001 for all comparisons vs. placebo). The greatest reduction
in LDL-C levels was attained with the two-dose 300-mg inclisiran regimen and 48% of the patients
who received that regimen had an LDL-C level < 50 mg/dL at day 180. Furthermore, the two-dose
300-mg inclisiran regimen caused a least-squares mean reduction in PCSK9 levels by 69.1% (p < 0.001
vs. placebo) and decreased high sensitivity C-reactive protein (hsCRP) by 16.7% (p < 0.05). Serious
adverse events occurred in 11% of the patients who received inclisiran and in 8% of the patients who
received placebo. Injection-site reactions occurred in 4% of patients who received one dose and in 7%
of patients who received two doses of inclisiran [24]. Thus, in this phase 2 trial, inclisiran produced
significant reductions in LDL-C and PCSK9 levels with an acceptable side effect profile, as compared
to placebo. However, given the relatively small number of patients and the short duration of the study,
no definitive conclusions can be drawn regarding the long-term side effect profile of inclisiran and
further larger studies with a longer follow-up period are required for that reason.

ORION-11 is an ongoing placebo-controlled, double-blind, randomized, phase 3 trial with
inclusiran. The study will enroll individuals with ASCVD or ASCVD-risk equivalents and elevated
LDL-C despite maximum tolerated dose of LDL-C lowering therapies in order to evaluate the efficacy,
safety, and tolerability of subcutaneous inclisiran injection(s). The study will be an international
multicenter study (non-United States). Currently, 1617 participants have been enrolled. The patients
will be randomly assigned to either inclisiran or placebo. Doses of 300 mg of inclisiran sodium
(equivalent to 284 mg of inclisiran) will be administered as subcutaneous injections on day 1, day 90,
and then every 6 months. Primary outcomes include percentage change in LDL-C from baseline to
day 510 and time-adjusted percent change in LDL-C levels from baseline between day 90 and day 540.
The secondary outcomes include absolute change in LDL-C from baseline to day 510, time-adjusted
absolute change in LDL-C from baseline between day 90 and day 540, as well as the percentage changes
in the levels of PCSK9, total cholesterol, apolipoprotein B (ApoB), and non-high-density lipoprotein
cholesterol (non-HDL-C) from baseline to day 510 [25].

ORION-11 trial is one of the four phase 3 pivotal trials with inclisiran. Others include the
ORION-10 trial with approximately 1500 ASCVD patients in North America, the ORION-9 trial with
approximately 400 patients with heterozygous familial hypercholesterolemia (FH) in North America,
Europe, Israel, and South Africa, as well as the ORION-5 trial with 60 patients with homozygous FH
in Europe, Middle East, and North America [26].

5. Conclusions and Future Directions

Medical interventions targeting PCSK9 have emerged as a very promising therapeutic strategy in
the management of hyperlipidemia. By inhibiting the expression of PCSK9, significant reductions in
the levels of LDL-C have been obtained that may lead to a reduction of cardiovascular risk [20]. As it
was mentioned before, two PCSK9 inhibitors (evolocumab and alirocumab) have already been tested
in large outcome trials and have been shown to significantly decrease cardiovascular risk [14,15].

On the other hand, inclisiran, a synthetic siRNA molecule, has been shown to significantly
decrease hepatic production of PCSK9 and cause a marked reduction in LDL-C levels [22–24], although,
up to date, there are no available studies showing the effect of inclisiran on intermediate CVD markers,
such as intima-media thickness of the carotid artery (CIMT), arterial flow-mediated dilation (FMD),
or arterial pulse wave velocity (PWV). Advantages of inclisiran over monoclonal antibodies directed
against PCSK9 include its infrequent administration (twice a year vs. 12–26 injections per year for
PCSK9 inhibitors), as well as the fact that anti-PCSK9 monoclonal antibodies act at a plasma level,
whereas inclisiran acts at the intracellular level of hepatocytes to mitigate the levels of LDL-C and
PCSK9 [27].

Furthermore, inclisiran appears to have a relatively benign side effect profile, as shown in the
ORION-1 trial. There were only rare symptoms of immune activation, such as flu-like symptoms,
which is often a concern with RNA-targeting therapies. In addition, inclisiran did not adversely affect
platelet levels, in contrast to other recent reports from studies of antisense oligonucleotides and other siRNA molecules [24,28]. However, the ongoing ORION-11 trial [25] is expected to better define the long-term side effect profile of inclisiran.

Notwithstanding, it is not yet ascertained that the marked LDL-C reductions attained with inclisiran would definitely translate into a reduction in CVD risk, and thus, large outcome trials would need to be conducted in the future for that reason.

Other potential future therapeutic strategies targeting PCSK9, which are currently in the initial stages of development, include small molecule inhibitors that disrupt the processing of PCSK9, the use of adnectins, which block the binding of PCSK9 to the LDL receptor [20,29], as well as the AT04A vaccine, which is currently being tested in a phase 1 clinical trial [20,30].

Funding: This research received no external funding.

Conflicts of Interest: C.E.K. and E.G. are members of the Dyslipidemia Speaker Bureau of Amgen, Inc. A.M.E., A.S., D.S., E.H. and P.D.M. declare no conflicts of interest.

References

1. World Health Organization. Cardiovascular Diseases (CVDs). Available online: http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed on 17 May 2017).
2. O’Keefe, J.H., Jr.; Cordain, L.; Harris, W.H.; Moe, R.M.; Vogel, R. Optimal low-density lipoprotein is 50 to 70 mg/dL: Lower is better and physiologically normal. J. Am. Coll. Cardiol. 2004, 43, 2142–2146. [CrossRef] [PubMed]
3. LaRosa, J.C.; Grundy, S.M.; Waters, D.D.; Shear, C.; Barter, P.; Fruchart, J.C.; Gotto, A.M.; Greten, H.; Kastelein, J.J.; Shepherd, J.; et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 2005, 352, 1425–1435. [CrossRef] [PubMed]
4. Waters, D.D. What the statin trials have taught us. Am. J. Cardiol. 2006, 98, 129–134. [CrossRef] [PubMed]
5. Grundy, S.M.; Cleeman, J.I.; Merz, C.N.; Brewer, H.B., Jr; Clark, L.T.; Hunninghake, D.B.; Pasternak, R.C.; Smith, S.C., Jr.; Stone, N.J.; National Heart, Lung, and Blood Institute; et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110, 227–239. [CrossRef] [PubMed]
6. Ridker, P.M.; Mora, S.; Rose, L.; JUPITER Trial Study Group. Percent reduction in LDL cholesterol following high-intensity statin therapy: Potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur. Heart J. 2016, 7, 1373–1379. [CrossRef] [PubMed]
7. Martin, S.S.; Gosch, K.; Kulkarni, K.R.; Spertus, J.A.; Mathews, R.; Ho, P.M.; Maddox, T.M.; Newby, L.K.; Alexander, K.P.; Wang, T.Y. Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. Am. Heart J. 2013, 165, 26–33. [CrossRef] [PubMed]
8. Virani, S.S.; Woodard, L.D.; Chitwood, S.S.; Landrum, C.R.; Uech, T.H.; Wang, D.; Murawsky, J.; Ballantyne, C.M.; Petersen, L.A. Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. Am. Heart J. 2011, 162, 725–732. [CrossRef] [PubMed]
9. Cohen, J.D.; Brinton, E.A.; Ito, M.K.; Jacobson, T.A. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. J. Clin. Lipidol. 2012, 6, 208–215. [CrossRef] [PubMed]
10. Kosmas, C.E.; Frishman, W.H. New and emerging LDL cholesterol-lowering drugs. Am. J. Ther. 2015, 22, 234–241. [CrossRef] [PubMed]
11. Seidah, N.G.; Benjannet, S.; Wickham, L.; Marcinkiewicz, J.; Jasmin, S.B.; Stifani, S.; Basak, A.; Prat, A.; Chretien, M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA 2003, 100, 928–933. [CrossRef] [PubMed]
12. Leren, T.P. Sorting an LDL receptor with bound PCSK9 to intracellular degradation. Atherosclerosis 2014, 237, 76–81. [CrossRef] [PubMed]
13. Cohen, J.C.; Boerwinkle, E.; Mosley, T.H., Jr.; Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 2006, 354, 1264–1272. [CrossRef] [PubMed]
14. Sabatine, M.S.; Giugliano, R.P.; Keech, A.C.; Honarpour, N.; Wiviott, S.D.; Murphy, S.A.; Kuder, J.F.; Wang, H.; Liu, T.; Wasserman, S.M.; et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N. Engl. J. Med.* 2017, 376, 1713–1722. [CrossRef] [PubMed]

15. Steg, P.G. Evaluation of Cardiovascular Outcomes after an Acute Coronary Syndrome during Treatment with Alirocumab—ODYSSEY OUTCOMES. In Proceedings of the American College of Cardiology Annual Scientific Session (ACC 2018), Orlando, FL, USA, 10–12 March 2018.

16. Carthew, R.W.; Sontheimer, E.J. Origins and Mechanisms of miRNAs and siRNAs. *Cell* 2009, 136, 642–655. [CrossRef] [PubMed]

17. Bernards, R. Exploring the uses of RNAi-gene knockdown and the Nobel Prize. *N. Engl. J. Med.* 2006, 355, 2391–2393. [CrossRef] [PubMed]

18. Agrawal, N.; Dasaradhi, P.V.; Mohmed, A.; Malhotra, P.; Bhatnagar, R.K.; Mukherjee, S.K. RNA interference: Biology, mechanism, and applications. *Microbiol. Mol. Biol. Rev.* 2003, 67, 657–685. [CrossRef] [PubMed]

19. Fitzgerald, K.; Frank-Kamenetsky, M.; Shulga-Morskaya, S.; Liebow, A.; Bettencourt, B.R.; Sutherland, J.E.; Hutabarat, R.M.; Clausen, V.A.; Karsten, V.; Cehelsky, J.; et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial. *Lancet* 2014, 383, 60–68. [CrossRef]

20. Nair, J.K.; Willoughby, J.L.; Chan, A.; Charisse, K.; Alam, M.R.; Wang, Q.; Hoekstra, M.; Kandasamy, P.; Kel’in, A.V.; Münster, S.; et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. *J. Am. Chem. Soc.* 2014, 136, 16958–16961. [CrossRef] [PubMed]

21. Bandyopadhyay, D.; Hajra, A.; Ashish, K.; Qureshi, A.; Ball, S. New hope for hyperlipidemia management: Inclisiran. *J. Cardiol.* 2018, 71, 523–524. [CrossRef] [PubMed]

22. Chi, X.; Gatti, P.; Papoian, T. Safety of antisense oligonucleotide and siRNA-based therapeutics. *Drug Discov. Today* 2017, 22, 823–833. [CrossRef] [PubMed]

23. Giugliano, R.P.; Sabatine, M.S. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? *J. Am. Coll. Cardiol.* 2015, 66, 2638–2651. [CrossRef] [PubMed]

24. Landlinger, C.; Pouwer, M.G.; Juno, C.; van der Hoorn, J.W.A.; Princen, H.M.G.; Galabova, G. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. *Eur. Heart J.* 2017, 38, 2499–2507. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).